NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity RFA-FD-18-019 from the NIH Guide for Grants and Contracts. The purpose of this project is to incorporate drug product quality attributes into dermal physiologically-based pharmacokinetic models developed for dermatological topical dosage forms and transdermal delivery systems. The developed models will be utilized to identify drug-product specific critical quality attributes (model qualification) and perform virtual bioequivalence assessments between brand name and generic drug products to inform regulatory decisions relating to the development of dermatological drug products.
Notice NOT-HL-18-609 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-18-715 from the NIH Guide for Grants and Contracts. This FOA invites existing Alzheimer's Disease Patient Registry cooperative agreements that are described in Part 2, Section I to submit revision and or renewal applications. Potential applicants are strongly encouraged to contact their current program officer prior to submission to discuss the application.
Notice NOT-NS-18-041 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DA-19-004 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to fund a single interdisciplinary Coordinating Center to formalize and centralize support of the rural opioid initiative administered by NIDA and co-funded by CDC, SAMHSA, and ARC. This initiative was funded under RFA-DA-17-014 and RFA-DA-17-023 The Coordinating Center will provide scientific, technical, regulatory, ethical, and logistical support of data comparability, new data collection, and data integration; developing integrated rural opioid initiative datasets; assisting grantees with acquisition and analysis of local administrative and/or research datasets that enable evaluation of their implementation activities or augment their community assessments; conducting requested analyses that relate to the integrated rural opioid initiative datasets; developing and executing a rural opioid initiative publication and dissemination plan; and providing logistical support for in-person meetings, conference calls, and webinars that include the rural opioid initiative grantees and funders. The Coordinating Center will be represented on the rural opioid initiative executive steering committee, along with the funders and rural opioid initiative grantees.
Notice NOT-AG-18-007 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-FD-18-017 from the NIH Guide for Grants and Contracts. The purpose of this project is to identify skin physiology characteristics that differ between healthy and skin disease population groups and incorporate them into dermal physiologically-based pharmacokinetic models to improve their predictability. The models developed will be utilized to perform virtual bioequivalence assessments between brand name and generic drug products to inform regulatory decisions relating to the development of generic topical dermatological drug products and transdermal delivery systems.
Notice NOT-AG-18-005 from the NIH Guide for Grants and Contracts
Notice NOT-EB-18-012 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-FD-18-010 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity is to support the research necessary to elucidate how systematic alterations to the qualitative (Q1) and/or quantitative (Q2) composition of topical formulations impacts their physical, structural, and functional properties. A key aspect of the research relates to understanding how the thermodynamic properties of a topical dosage form change as it undergoes metamorphosis during dose application and drying on the skin, how the drug's thermodynamic activity profile during the metamorphosis of the dosage form may compare between compositionally different (non-Q1 and/or non-Q2) topical formulations, and how these and other forces may modulate the rate and extent to which topically applied drugs may become available at or near their site(s) of action in the skin. Another key aspect of the research relates to identifying and understanding other potential failure modes for bioequivalence (BE) and/or therapeutic equivalence (TE) (e.g., differences in irritation potential) that may arise between compositionally different (non-Q1 and/or non-Q2) topical formulations.
Notice NOT-CA-18-057 from the NIH Guide for Grants and Contracts
Notice NOT-RM-18-016 from the NIH Guide for Grants and Contracts
Notice NOT-NR-18-005 from the NIH Guide for Grants and Contracts
Notice NOT-DK-18-011 from the NIH Guide for Grants and Contracts
Notice NOT-NR-18-006 from the NIH Guide for Grants and Contracts
Notice NOT-MH-18-025 from the NIH Guide for Grants and Contracts
Notice NOT-NR-18-003 from the NIH Guide for Grants and Contracts
Notice NOT-HL-18-605 from the NIH Guide for Grants and Contracts
Notice NOT-EB-18-007 from the NIH Guide for Grants and Contracts
Notice NOT-CA-18-032 from the NIH Guide for Grants and Contracts